{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:55Z","timestamp":1790812735001,"version":"4.1.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,6,21]]},"abstract":"<jats:p>Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being developed for the treatment of HIV-1 infection.<\/jats:p>","DOI":"10.1128\/aac.00133-22","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:22:25Z","timestamp":1652347345000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-8641","authenticated-orcid":true,"given":"Tracy L.","family":"Diamond","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc., Infectious Disease and Vaccines, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Ngo","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Infectious Disease and Vaccines, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Quantitative Biosciences, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih Lin","family":"Goh","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Quantitative Biosciences, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silveria","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Quantitative Biosciences, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tain","family":"Lai","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Infectious Disease and Vaccines, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-6529","authenticated-orcid":true,"given":"Ernest","family":"Asante-Appiah","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Infectious Disease and Vaccines, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Grobler","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Infectious Disease and Vaccines, Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"40","article-title":"The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase","volume":"57","author":"Kirby KA","year":"2011","unstructured":"Kirby KA, Singh K, Michailidis E, Kodama EN, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2011. The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell Mol Biol (Noisy-le-grand) 57:40\u201346.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.562694"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.036616"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.03.001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00021-7"},{"key":"e_1_3_2_7_2","volume-title":"PIFELTROTM (doravirine) prescribing information.","author":"Merck Sharp & Dohme Corp.","year":"2019","unstructured":"Merck Sharp & Dohme Corp. 2019. PIFELTROTM (doravirine) prescribing information. Merck Sharp & Dohme Corp., Whitehouse Station, NJ."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.04.007"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2697"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.07.014"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01167-21"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002834"},{"key":"e_1_3_2_13_2","volume-title":"Conference on retroviruses and opportunistic infections","author":"Rudd DJ","year":"2020","unstructured":"Rudd DJ, Cao Y, Vaddady P, Grobler JA, Asante-Appiah E, Diamond T, Klopfer S, Grandhi A, Sklar P, Hwang C, Vargo R. 2020. Modeling-supported islatravir dose selection for phase 3, abstr 462. Conference on retroviruses and opportunistic infections, Boston, MA."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.13.9251"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00777.x"},{"key":"e_1_3_2_16_2","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer RW","year":"2008","unstructured":"Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10:67\u201384.","journal-title":"AIDS Rev"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000599"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00723-12"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.13.4803"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/327716a0"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041056"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.11.004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2010.02.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90097-7"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.59.2.284-291.1986"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00133-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00133-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T10:50:29Z","timestamp":1655808629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00133-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,21]]}},"alternative-id":["10.1128\/aac.00133-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00133-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2022-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00133-22"}}